# US administration prescription drug pricing policies

> Live situation record from CLSTR: https://clstr.news/situations/us-administration-prescription-drug-pricing-policies
> Updated: 2026-08-31T14:44:38.000Z. Sources: 3. Developments: 2.

The Trump administration has focused on reducing costs for prescription drugs, with the White House claiming credit for a significant year-over-year decline in prices. While the administration attributes these shifts to its own actions, reports suggest experts link the drop to Biden-era policies, specifically the Inflation Reduction Act, which enables Medicare to negotiate prices for certain high-expenditure drugs.

To further address healthcare affordability, the administration announced new voluntary ‘Most Favored Nation’ (MFN) drug-pricing agreements. Under this framework, manufacturers such as Bayer, Takeda, and CSL agree to align U.S. prices with the lowest prices found in other high-income nations like Canada and Japan. The administration noted that previous MFN deals contributed to a 3.1% year-over-year drop in prescription drug prices.

## Timeline

### 2026-08-31: Trump administration targets drug and gas affordability

President Trump is advancing drug-pricing agreements through the Most Favored Nation framework to lower costs, while gas prices decline and critics warn a new Department of Labor rule could increase expenses.

3 sources. https://clstr.news/cluster/trump-administration-targets-drug-and-gas-affordability

### 2026-08-15: Trump claims credit for major drop in prescription drug prices

The White House is claiming credit for a major drop in prescription drug prices, though experts cited in a Washington Post report attribute the decline to Biden-era Medicare negotiation policies.

8 sources. https://clstr.news/cluster/trump-claims-credit-for-major-drop-in-prescription-drug-prices

---
Cite as: US administration prescription drug pricing policies. CLSTR, https://clstr.news/situations/us-administration-prescription-drug-pricing-policies